Cadrenal Therapeutics (CVKD) Revenue & Revenue Breakdown
Cadrenal Therapeutics Revenue Highlights
00
Cadrenal Therapeutics Revenue by Period
Cadrenal Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | - |
Cadrenal Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Cadrenal Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.77K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | - |
Cadrenal Therapeutics generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Cadrenal Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
| IKNA | Ikena Oncology | $9.16M | - |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| HCWB | HCW Biologics | $2.84M | $426.42K |
| SNTI | Senti Biosciences | $2.56M | - |
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| IKT | Inhibikase Therapeutics | $260.50K | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| GPCR | Structure Therapeutics | - | - |
| XCUR | Exicure | - | - |
| ANTX | AN2 Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| CVKD | Cadrenal Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
| ENOB | Renovaro Biosciences | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |